UroGen Pharma (URGN) Short Interest Ratio & Short Volume $16.35 -0.01 (-0.06%) (As of 07/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends UroGen Pharma Short Interest DataCurrent Short Interest5,870,000 sharesPrevious Short Interest6,340,000 sharesChange Vs. Previous Month-7.41%Dollar Volume Sold Short$105.19 millionShort Interest Ratio9.5 Days to CoverLast Record DateJuly 15, 2024Outstanding Shares23,450,000 sharesPercentage of Shares Shorted25.03%Today's Trading Volume314,828 sharesAverage Trading Volume500,405 sharesToday's Volume Vs. Average63% Short Selling UroGen Pharma ? Sign up to receive the latest short interest report for UroGen Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartURGN Short Interest Over TimeURGN Days to Cover Over TimeURGN Percentage of Float Shorted Over Time Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. UroGen Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/20245,870,000 shares $105.19 million -7.4%N/A9.5 $17.92 6/30/20246,340,000 shares $106.39 million +12.8%N/A10.5 $16.78 6/15/20245,620,000 shares $107.90 million +6.8%N/A9.8 $19.20 5/31/20245,260,000 shares $69.96 million +17.7%N/A15.5 $13.30 5/15/20244,470,000 shares $61.60 million +0.9%N/A13.7 $13.78 4/30/20244,430,000 shares $61.22 million +5.5%N/A12.7 $13.82 Get the Latest News and Ratings for URGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. 4/15/20244,200,000 shares $63.42 million +0.2%N/A11.5 $15.10 3/31/20244,190,000 shares $62.85 million -1.4%N/A12.6 $15.00 3/15/20244,250,000 shares $61.46 million +8.1%N/A12.4 $14.46 2/29/20243,930,000 shares $72.04 million -2.0%N/A12.7 $18.33 2/15/20244,010,000 shares $75.39 million +23.0%N/A13.2 $18.80 1/31/20243,260,000 shares $51.18 million -3.8%N/A11 $15.70 1/15/20243,390,000 shares $49.46 million -4.5%N/A12.9 $14.59 12/31/20233,550,000 shares $53.25 million +15.6%N/A13.5 $15.00 12/15/20233,070,000 shares $46.05 million +5.1%N/A11.3 $15.00 11/30/20232,920,000 shares $38.51 million +3.2%N/A12.4 $13.19 11/15/20232,830,000 shares $32.77 million +23.6%N/A11.4 $11.58 10/31/20232,290,000 shares $25.67 million +39.6%N/A7.9 $11.21 10/15/20231,640,000 shares $21.48 million +14.7%N/A2.6 $13.10 9/30/20231,430,000 shares $20.03 million +10.9%N/A2.3 $14.01 9/15/20231,290,000 shares $20.52 million -8.5%N/A2.1 $15.91 8/31/20231,410,000 shares $24.65 million -15.1%N/A2.2 $17.48 8/15/20231,660,000 shares $37.12 million +5.7%N/A2.7 $22.36 7/31/20231,570,000 shares $34.01 million +55.5%N/A2.8 $21.66 7/15/20231,010,000 shares $9.28 million +11.1%5.1%4 $9.19 6/30/2023909,100 shares $9.41 million +38.5%4.6%3.8 $10.35 6/15/2023656,300 shares $8.07 million -23.0%3.3%2.7 $12.29 5/31/2023852,100 shares $8.44 million -9.8%4.3%4.6 $9.90 5/15/2023944,700 shares $11.16 million +29.3%4.8%5.4 $11.81 4/30/2023730,500 shares $8.47 million -1.8%3.7%4.3 $11.59 4/15/2023743,700 shares $7.16 million +16.3%3.8%5.8 $9.63 3/31/2023639,500 shares $5.91 million +2.3%3.3%5.6 $9.24 3/15/2023625,300 shares $6.02 million +5.5%3.3%6.3 $9.63 2/28/2023592,900 shares $6.11 million +2.8%3.1%6.7 $10.30 2/15/2023576,700 shares $5.29 million +1.2%3.0%6.4 $9.17 1/31/2023569,700 shares $5.92 million +0.0%3.0%6.6 $10.39 1/15/2023569,600 shares $4.88 million -15.2%2.9%7.7 $8.56 12/30/2022671,700 shares $5.96 million -0.2%3.5%8.9 $8.87 12/15/2022673,000 shares $5.32 million +0.1%3.5%10.2 $7.91 11/30/2022672,600 shares $5.76 million -1.0%3.5%10.3 $8.57Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad)In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. 11/15/2022679,700 shares $6.17 million -9.5%3.5%10.5 $9.08 10/31/2022751,100 shares $8.90 million -31.7%3.9%13 $11.85 10/15/20221,100,000 shares $12.65 million -20.3%5.8%19.5 $11.50 9/30/20221,380,000 shares $11.48 million -3.5%7.2%25.6 $8.32 9/15/20221,430,000 shares $13.46 million +1.4%7.5%15 $9.41 8/31/20221,410,000 shares $10.50 million -3.4%7.3%13 $7.45 8/15/20221,460,000 shares $12.64 million -0.7%7.6%10.3 $8.66 7/31/20221,470,000 shares $11.52 million -3.3%7.7%8.9 $7.84 7/15/20221,520,000 shares $13.77 million -10.6%7.9%8.4 $9.06 6/30/20221,700,000 shares $13.92 million -22.0%8.9%8.7 $8.19 6/15/20222,180,000 shares $14.72 million -10.7%11.4%10.6 $6.75 5/31/20222,440,000 shares $12.98 million +3.4%12.7%14.6 $5.32 5/15/20222,360,000 shares $14.04 million +3.5%12.3%15.8 $5.95 4/30/20222,280,000 shares $16.10 million +10.1%11.9%17 $7.06 4/15/20222,070,000 shares $16.21 million +4.6%10.8%15.7 $7.83 3/31/20221,980,000 shares $17.25 million -10.0%10.4%14.9 $8.71 3/15/20222,200,000 shares $18.55 million -0.5%11.6%16.7 $8.43 2/28/20222,210,000 shares $13.26 million +11.1%11.7%15.8 $6.00 2/15/20221,990,000 shares $14.23 million No Change10.5%14.5 $7.15 1/31/20221,990,000 shares $15.36 million +7.6%10.5%12.8 $7.72 1/15/20221,850,000 shares $15.71 million +2.2%9.8%12.2 $8.49 12/31/20211,810,000 shares $17.21 million -4.2%9.5%13.8 $9.51 12/15/20211,890,000 shares $19.18 million +3.9%9.9%16.3 $10.15 11/30/20211,820,000 shares $22.00 million +11.0%9.6%17.9 $12.09 11/15/20211,640,000 shares $24.17 million -6.3%8.6%16.8 $14.74 10/29/20211,750,000 shares $30.10 million -0.6%9.2%22.4 $17.20 10/15/20211,760,000 shares $29.96 million -4.9%9.3%20.8 $17.02 9/30/20211,850,000 shares $31.12 million -10.2%9.8%16.5 $16.82 9/15/20212,060,000 shares $31.37 million -6.8%10.9%16.1 $15.23 8/31/20212,210,000 shares $38.94 million -0.5%11.7%16.3 $17.62 8/13/20212,220,000 shares $33.59 million +7.8%11.7%16.1 $15.13 7/30/20212,060,000 shares $31.93 million -1.4%10.9%13.8 $15.50 7/15/20212,090,000 shares $32.19 million -1.9%11.1%14.8 $15.40 6/30/20212,130,000 shares $32.53 million -6.2%11.3%16.1 $15.27 6/15/20212,270,000 shares $38.79 million -7.4%12.0%17.4 $17.09 5/28/20212,450,000 shares $43.17 million +5.2%13.0%16.2 $17.62 5/14/20212,330,000 shares $35.84 million -0.4%12.3%13 $15.38 4/30/20212,340,000 shares $47.20 million -1.3%12.4%12.9 $20.17 4/15/20212,370,000 shares $41.78 million +1.7%12.5%12 $17.63 3/31/20212,330,000 shares $43.15 million -4.9%12.3%11.2 $18.52 3/15/20212,450,000 shares $48.00 million -11.2%12.9%11.1 $19.59 2/26/20212,760,000 shares $55.89 million +1.5%14.7%13.6 $20.25 2/12/20212,720,000 shares $70.94 million +3.8%14.5%14.8 $26.08 1/29/20212,620,000 shares $58.61 million -0.8%13.9%14.6 $22.37 1/15/20212,640,000 shares $55.26 million -1.9%14.0%15.3 $20.93 12/31/20202,690,000 shares $48.66 million +8.9%14.3%17.4 $18.09 12/15/20202,470,000 shares $45.97 million -9.5%13.1%17.9 $18.61 11/30/20202,730,000 shares $55.97 million +2.6%14.4%21.2 $20.50 10/30/20203,010,000 shares $69.20 million -3.8%16.0%20.1 $22.99 10/15/20203,130,000 shares $70.77 million -1.6%16.6%20.5 $22.61Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad)In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. 9/30/20203,180,000 shares $61.34 million -0.6%16.9%20.5 $19.29 9/15/20203,200,000 shares $70.43 million +2.9%17.0%20.1 $22.01 8/31/20203,110,000 shares $78.03 million -0.6%16.5%19.7 $25.09 8/14/20203,130,000 shares $71.83 million +2.3%16.6%21 $22.95 7/31/20203,060,000 shares $67.60 million +2.3%17.0%18.9 $22.09 7/15/20202,990,000 shares $70.89 million +5.7%16.7%15.8 $23.71 6/30/20202,830,000 shares $73.92 million +5.2%15.9%11.7 $26.12 6/15/20202,690,000 shares $71.55 million -2.9%15.1%10.6 $26.60 5/29/20202,770,000 shares $66.48 million +1.8%16.1%10 $24.00 5/15/20202,720,000 shares $67.05 million +3.0%15.8%9.9 $24.65 4/30/20202,640,000 shares $64.34 million +3.1%14.2%10.2 $24.37 4/15/20202,560,000 shares $53.86 million +10.3%14.9%11 $21.04 3/31/20202,320,000 shares $41.39 million +9.1%13.5%11.9 $17.84 3/13/20202,126,500 shares $45.29 million -11.8%13.4%9.7 $21.30 2/28/20202,410,000 shares $39.09 million +1.3%15.1%14.7 $16.22 2/14/20202,380,000 shares $65.83 million -0.8%14.0%14.8 $27.66 1/31/20202,400,000 shares $68.26 million +13.2%14.1%14 $28.44 1/15/20202,120,000 shares $63.54 million +17.8%12.5%11.8 $29.97 12/31/20191,800,000 shares $54.81 million -24.4%10.6%11 $30.45 URGN Short Interest - Frequently Asked Questions What is UroGen Pharma's current short interest? Short interest is the volume of UroGen Pharma shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 5,870,000 shares of URGN short. Learn More on UroGen Pharma's current short interest. What is a good short interest ratio for UroGen Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. URGN shares currently have a short interest ratio of 10.0. Learn More on UroGen Pharma's short interest ratio. Is UroGen Pharma's short interest increasing or decreasing? UroGen Pharma saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 5,870,000 shares, a decrease of 7.4% from the previous total of 6,340,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does UroGen Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to UroGen Pharma: Akebia Therapeutics, Inc. (8.90%), Puma Biotechnology, Inc. (10.94%), RAPT Therapeutics, Inc. (10.40%), Marinus Pharmaceuticals, Inc. (4.92%), Wave Life Sciences Ltd. (3.17%), Indivior PLC (0.45%), Belite Bio, Inc (0.96%), Nurix Therapeutics, Inc. (13.72%), Dynavax Technologies Co. (13.15%), Day One Biopharmaceuticals, Inc. (19.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.13 billion), Royal Caribbean Cruises Ltd. ($2.77 billion), Moderna, Inc. ($2.76 billion), Coinbase Global, Inc. ($2.36 billion), Rivian Automotive, Inc. ($2.22 billion), Paychex, Inc. ($2.02 billion), Tractor Supply ($1.81 billion), Enphase Energy, Inc. ($1.65 billion), Chesapeake Energy Co. ($1.62 billion), and Lululemon Athletica Inc. ($1.58 billion). View all of the most shorted stocks. What does it mean to sell short UroGen Pharma stock? Short selling URGN is an investing strategy that aims to generate trading profit from UroGen Pharma as its price is falling. URGN shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against UroGen Pharma? A short squeeze for UroGen Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of URGN, which in turn drives the price of the stock up even further. How often is UroGen Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including URGN, twice per month. The most recent reporting period available is July, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Akebia Therapeutics Short Interest Data Puma Biotechnology Short Interest Data RAPT Therapeutics Short Interest Data Marinus Pharmaceuticals Short Interest Data Wave Life Sciences Short Interest Data Indivior Short Interest Data Belite Bio Short Interest Data Nurix Therapeutics Short Interest Data Dynavax Technologies Short Interest Data Day One Biopharmaceuticals Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:URGN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.